Administration of Tivozanib via Gastrostomy Tube: A Pharmacokinetic Analysis

Author(s)Catherine Chen, PharmD, BCOP, Erik B. Harrington, PharmD, MS, BCOP, Autumn McKnite, PhD

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Tivozanib is an oral multikinase inhibitor targeting VEGFR-1,-2, and 3; c-KIT; and PDGFR-b. In the phase 3 TIVO-3 trial, tivozanib improved median progression-free survival (5.6 vs 3.9 months) over sorafenib, leading to FDA approval for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). To our knowledge, there are no published data on the administration of tivozanib via enteral tubes.